New Survey Data Reveals Nearly 75% of Consumers Have Not Had a Full Skin Exam Within the Past 12 Months
01 Maio 2023 - 5:30PM
Business Wire
To elevate the importance of regular skin
checks, DermTech announces its third annual #Stickit2Melanoma
campaign for Melanoma Awareness Month
DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a
leader in precision dermatology enabled by a non-invasive skin
genomics platform, today announced the release of new survey data
in conjunction with the launch of its third annual
#Stickit2Melanoma campaign in honor of Melanoma and Skin Cancer
Awareness Month in May. Initiated in 2021, the campaign aims to
raise awareness of melanoma, one of the deadliest forms of skin
cancer, and promote the importance of scheduling regular skin
exams.
The national survey gathered responses from more than 500
consumers, with only 22% reporting a previous diagnosis of
melanoma. According to the findings, almost three fourths of
respondents (74.2%) have not received a full skin exam within the
past 12 months, despite 48.9% of respondents admitting they
currently have – or are not sure if they have – new or changing
moles. Additionally, about 55% of respondents said that they have
either never visited a dermatologist or have not visited a
dermatologist in more than two years. Finally, only 23.48% of
respondents said that they were prompted to visit a dermatologist
for a skin cancer screening.
“Too many people are not scheduling skin exams, despite the fact
that early melanoma detection is key for positive treatment
outcomes,” said Todd Wood, chief commercial officer of DermTech.
“With this top-of-mind, we’re proud to launch our third annual
#Stickit2Melanoma campaign and continue to raise awareness of the
dangers of melanoma, a potentially life-threatening disease, and
encourage people to schedule skin exams with their doctors today.
We are passionate about empowering individuals to take proactive
steps in protecting their health, screening for skin cancer and
joining us in this important fight against melanoma."
The #Stickit2Melanoma campaign officially begins today, May 1,
2023, known as Melanoma Monday. For every #Stickit2Melanoma pledge
to schedule a skin exam, DermTech will make a $5 donation to its
non-profit partner organizations – all of which, along with
DermTech, are dedicated to helping end deaths from melanoma. The
campaign will support events, educational content and programs
throughout the year. Since 2021, DermTech has donated $500,000 and
has committed to donating up to $1 million through 2025.
In tandem with the observance, DermTech is distributing pledge
stickers to doctors’ offices across the country, allowing patients
to take the skin exam pledge in-person, along with UV bracelets
that change color when the wearer should consider getting out of
the sun.
To join #Stickit2Melanoma and find a specialist to schedule a
skin exam, visit https://dermtech.com/pledge/. To learn more about
the DermTech Melanoma Test, visit https://dermtech.com/.
About DermTech
DermTech is a leading genomics company in dermatology and is
creating a new category of medicine, precision dermatology, enabled
by its non-invasive skin genomics platform. DermTech’s mission is
to improve the lives of millions by providing non-invasive
precision dermatology solutions that enable individualized care.
DermTech provides genomic analysis of skin samples collected
non-invasively using its Smart Stickers™. DermTech markets and
develops products that facilitate the early detection of skin
cancers and is developing products that assess inflammatory
diseases and customize drug treatments. For additional information,
please visit DermTech.
Forward-Looking Statements
This press release includes “forward-looking statements” within
the meaning of the “safe harbor” provisions of the Private
Securities Litigation Reform Act of 1995. The expectations,
estimates, and projections of DermTech may differ from its actual
results and consequently, you should not rely on these
forward-looking statements as predictions of future events. Words
such as “expect,” “estimate,” “project,” “budget,” “forecast,”
"outlook," “anticipate,” “intend,” “plan,” “may,” “will,” “could,”
“should,” “believes,” “predicts,” “potential,” “continue,” and
similar expressions are intended to identify such forward-looking
statements. These forward-looking statements include, without
limitation, expectations and evaluations with respect to: the
performance, patient benefits, cost- effectiveness,
commercialization and adoption of DermTech’s products and the
market opportunity for these products, DermTech’s positioning and
potential revenue growth, financial outlook and future financial
performance, ability to maintain or improve its operating
efficiency, implications and interpretations of any study results,
expectations regarding reimbursement or cash collection patterns
from Medicare from commercial payors and related billing practices
or number of covered lives, and DermTech’s ability to expand its
product offerings and develop pipeline products. These
forward-looking statements involve significant risks and
uncertainties that could cause the actual results to differ
materially from the expected results. Most of these factors are
outside of the control of DermTech and are difficult to predict.
Factors that may cause such differences include, but are not
limited to: (1) the outcome of any legal proceedings that may be
instituted against DermTech; (2) DermTech’s ability to obtain
additional funding to develop and market its products; (3) the
existence of favorable or unfavorable clinical guidelines for
DermTech’s tests; (4) the reimbursement of DermTech’s tests by
Medicare and commercial payors; (5) the ability of patients or
healthcare providers to obtain coverage of or sufficient
reimbursement for DermTech’s products; (6) DermTech’s ability to
grow, manage growth and retain its key employees; (7) changes in
applicable laws or regulations; (8) the market adoption and demand
for DermTech’s products and services together with the possibility
that DermTech may be adversely affected by other economic,
business, and/or competitive factors; and (9) other risks and
uncertainties included in the “Risk Factors” section of the most
recent Annual Report on Form 10-K filed by DermTech with the
Securities and Exchange Commission (the “SEC”), and other documents
filed or to be filed by DermTech with the SEC, including
subsequently filed reports. DermTech cautions that the foregoing
list of factors is not exclusive. You should not place undue
reliance upon any forward- looking statements, which speak only as
of the date made. DermTech does not undertake or accept any
obligation or undertaking to release publicly any updates or
revisions to any forward-looking statements to reflect any change
in its expectations or any change in events, conditions, or
circumstances on which any such statement is based.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230501005202/en/
Steve Kunszabo DermTech (858) 291-1647
steve.kunszabo@dermtech.com
DermTech (NASDAQ:DMTK)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
DermTech (NASDAQ:DMTK)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024